These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34677089)

  • 1. Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States.
    Yang J; Carioto J; Pyenson B; Smith R; Jacobson N; Pittinger S; Shelbaya A
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1642-1651. PubMed ID: 34677089
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
    Grewal S; Ramsey S; Balu S; Carlson JJ
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative.
    Edgar BS; Cheifetz AS; Helfgott SM; Smith GP; Bandekar T; Hoye-Simek A; Liu Y; Singh RM; Fajardo KI; Carter J; Simone L
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1129-1135. PubMed ID: 34337986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic implications of biosimilars.
    Singh SC; Bagnato KM
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study.
    Yang J; Chaudhry BI; Yue AT; Roth JA; Kelton JM; Shelbaya A; Tran L; Li M
    Adv Ther; 2024 Jan; 41(1):349-363. PubMed ID: 37957523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
    Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
    BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
    Spencer SJ; Guzauskas GF; FeLizzi F; Launonen A; Dawson K; Veenstra DL; Masaquel A
    J Manag Care Spec Pharm; 2021 May; 27(5):615-624. PubMed ID: 33586513
    [No Abstract]   [Full Text] [Related]  

  • 8. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Following the Biosimilar Breadcrumbs: When Health Systems and Manufacturers Approach Forks in the Road.
    Oskouei ST
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1245-1248. PubMed ID: 29172974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives.
    Yang J; Liu R; Ektare V; Stephens J; Shelbaya A
    Appl Health Econ Health Policy; 2021 Jul; 19(4):605-618. PubMed ID: 33506318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health insurance coverage and switching among people with hemophilia A in the United States.
    He C; Hinds D; Pezalla E; Cheng D; Chen E; Sammon J; Solari PG; Recht M
    J Manag Care Spec Pharm; 2022 Feb; 28(2):232-243. PubMed ID: 34780299
    [No Abstract]   [Full Text] [Related]  

  • 12. Stakeholder perspectives on the sustainability of the United States biosimilars market.
    Sullivan SD; Humphreys SZ; Fox D; Lockhart CM; Tait-Dinger A; Betancourt JD; Komorny KM; Haumschild R; Chester B; Harman M; Roth JA
    J Manag Care Spec Pharm; 2024 Oct; 30(10):1065-1072. PubMed ID: 39012302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations of the Medicare Payment Advisory Commission (MEDPAC) on the Health Care Delivery System: the impact on interventional pain management in 2014 and beyond.
    Manchikanti L; Benyamin RM; Falco FJ; Hirsch JA
    Pain Physician; 2013; 16(5):419-40. PubMed ID: 24077189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs.
    Reese R; Nanavath SR; Martin J; Travers JB; Rohan CA
    J Dermatolog Treat; 2024 Dec; 35(1):2402912. PubMed ID: 39278830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars: Opportunities to Promote Optimization Through Payer and Provider Collaboration.
    Manolis CH; Rajasenan K; Harwin W; McClelland S; Lopes M; Farnum C
    J Manag Care Spec Pharm; 2016 Sep; 22(9 Suppl):S3-9. PubMed ID: 27579939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Projected US savings from biosimilars, 2021-2025.
    Mulcahy A; Buttorff C; Finegold K; El-Kilani Z; Oliver JF; Murphy S; Jessup A
    Am J Manag Care; 2022 Jul; 28(7):329-335. PubMed ID: 35852882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.
    Baker JF; Leonard CE; Lo Re V; Weisman MH; George MD; Kay J
    Arthritis Rheumatol; 2020 Jul; 72(7):1067-1071. PubMed ID: 32253823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities and challenges in biosimilar uptake in oncology.
    Dolan C
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.